001065.KS
JW Pharmaceutical Corporation [001065.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
001065.KS Stock Summary
Top 001065.KS Correlated Resources
001065.KS
Top 10 Correlated Stocks
001065.KS
In the News
001065.KS Financial details
Company Rating
Strong Buy
Market Cap
797.67B
Income
12.13B
Revenue
660.66B
Book val./share
2035.71
Cash/share
-
Dividend
400
Dividend %
1.23%
Employees
1.13K
Optionable
No
Shortable
Yes
Earnings
-
P/E
281.46
Forward P/E
-
PEG
-23.77
P/S
5.17
P/B
15.94
P/C
-
P/FCF
104.58
Quick Ratio
-
Current Ratio
1.22
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
115.29
EPS next Y
-
EPS next Q
-
EPS this Y
-98.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-21.28%
Revenue last 5Y
3.82%
Revenue Q/Q
2.93%
EPS Q/Q
744.09%
-
-
-
-
SMA20
-0.02%
SMA50
-9.17%
SMA100
-10.89%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
6%
ROC
0.16%
Gross Margin
40%
Oper. Margin
7%
Profit Margin
2%
Payout
347%
Shs Outstand
20.1M
Shs Float
11.41M
-
-
-
-
Target Price
-
52W Range
28900.0-39000.0
52W High
-16.79%
52W Low
+12.28%
RSI
46.14
Rel Volume
0.29
Avg Volume
341
Volume
98
Perf Week
-0.92%
Perf Month
-6.75%
Perf Quarter
-11.46%
Perf Half Y
-9.86%
-
-
-
-
Beta
0.333218
-
-
Volatility
390.45%, 1147.31%
Prev Close
0.78%
Price
32450
Change
1.41%
001065.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 20.68K | 22.09K | 21.03K | 22.51K | 5.78K | |
| Net income per share | -30.53 | 331.3 | -1.04K | -626.72 | -9.23 | |
| Operating cash flow per share | 1.38K | 2.14K | 2.28K | 2.59K | 172.78 | |
| Free cash flow per share | 925.17 | 1.8K | 1.74K | 1.97K | 49.79 | |
| Cash per share | 1.32K | 1.27K | 1.72K | 2.27K | 625.99 | |
| Book value per share | 11.13K | 10.7K | 9.46K | 8.53K | 1.92K | |
| Tangible book value per share | 10.31K | 10.07K | 8.58K | 7.8K | 1.59K | |
| Share holders equity per share | 11.13K | 10.7K | 9.46K | 8.53K | 1.92K | |
| Interest debt per share | 8.19K | 7.56K | 8.17K | 7.8K | 2.41K | |
| Market cap | 589.93B | 589.12B | 617.78B | 819.29B | 3514.12B | |
| Enterprise value | 748.19B | 733.39B | 763.44B | 991.06B | 3725.89B | |
| P/E ratio | -794.55 | 73.12 | -24.44 | -53.75 | -3.63K | |
| Price to sales ratio | 1.17 | 1.1 | 1.21 | 1.5 | 5.79 | |
| POCF ratio | 17.64 | 11.31 | 11.12 | 12.99 | 193.89 | |
| PFCF ratio | 26.22 | 13.46 | 14.56 | 17.06 | 672.89 | |
| P/B Ratio | 2.18 | 2.26 | 2.69 | 3.95 | 17.47 | |
| PTB ratio | 2.18 | 2.26 | 2.69 | 3.95 | 17.47 | |
| EV to sales | 1.49 | 1.37 | 1.49 | 1.81 | 6.14 | |
| Enterprise value over EBITDA | 28.43 | 20.04 | -281.95 | 65.61 | 83.81 | |
| EV to operating cash flow | 22.37 | 14.07 | 13.75 | 15.72 | 205.58 | |
| EV to free cash flow | 33.25 | 16.76 | 17.99 | 20.64 | 713.45 | |
| Earnings yield | 0 | 0.01 | -0.04 | -0.02 | 0 | |
| Free cash flow yield | 0.04 | 0.07 | 0.07 | 0.06 | 0 | |
| Debt to equity | 0.05 | 0.18 | 0.14 | 0.36 | 0.61 | |
| Debt to assets | 0.57 | 0.56 | 0.6 | 0.62 | 0.7 | |
| Net debt to EBITDA | 6.01 | 3.94 | -53.8 | 11.37 | 4.76 | |
| Current ratio | 1.5 | 1.64 | 1.21 | 1.28 | 1.3 | |
| Interest coverage | 2.45 | 2.48 | -1.69 | -0.17 | 4.25 | |
| Income quality | -45.05 | 6.47 | -2.2 | -4.14 | -18.73 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Payout ratio | -7.93 | 0.81 | -0.27 | -0.46 | -7.39 | |
| Sales general and administrative to revenue | 0.12 | 0.12 | 0.08 | 0.12 | 0.14 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.05 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.33 | -0.16 | -0.24 | -0.24 | -0.71 | |
| Capex to revenue | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | |
| Capex to depreciation | -0.58 | -0.47 | -0.64 | -0.73 | -0.8 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.77K | 8.93K | 14.87K | 10.97K | 631 | |
| ROIC | 0.06 | 0.06 | -0.06 | 0 | 0.09 | |
| Return on tangible assets | 0 | 0.01 | -0.05 | -0.03 | 0 | |
| Graham Net | -11.3K | -10.36K | -10.53K | -9.69K | -3.12K | |
| Working capital | 136.83B | 145.54B | 57.07B | 64.58B | 83.77B | |
| Tangible asset value | 250.64B | 244.97B | 208.7B | 189.8B | 167.07B | |
| Net current asset value | 51.27B | 40.23B | -8.06B | -42.29B | -78.06B | |
| Invested capital | 0.7 | 0.67 | 0.82 | 0.88 | 1.22 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 53.74B | 46.17B | 46.49B | 47.89B | 49.76B | |
| Average inventory | 103.91B | 101.28B | 95.82B | 101.2B | 101.86B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 69.2 | 47.71 | 46.99 | 47.26 | 50.64 | |
| Days of inventory on hand | 123.83 | 108.78 | 94.26 | 99.88 | 100.54 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.27 | 7.65 | 7.77 | 7.72 | 7.21 | |
| Inventory turnover | 2.95 | 3.36 | 3.87 | 3.65 | 3.63 | |
| ROE | 0 | 0.03 | -0.11 | -0.07 | 0 | |
| Capex per share | -450.3 | -343.15 | -538.52 | -618.41 | -122.99 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 6.13K | 1.61K | 1.49K | 1.57K | 1.61K | |
| Net income per share | 209.32 | -63.93 | 91.09 | 9.34 | 78.8 | |
| Operating cash flow per share | 927.64 | 124.58 | 54.89 | 87.58 | 173.43 | |
| Free cash flow per share | 794.86 | 84.65 | 18.8 | 66.33 | 140.52 | |
| Cash per share | 2.85K | 624.11 | 659.84 | 662.59 | 0 | |
| Book value per share | 8.49K | 1.91K | 1.93K | 1.95K | 2.04K | |
| Tangible book value per share | 7.73K | 1.59K | 1.62K | 1.63K | 1.91K | |
| Share holders equity per share | 8.49K | 1.91K | 1.93K | 1.95K | 2.04K | |
| Interest debt per share | 8.86K | 2.36K | 2.42K | 2.34K | 5.39 | |
| Market cap | 759.09B | 3577.34B | 3982.43B | 3824.6B | 3530B | |
| Enterprise value | 945.61B | 3789.12B | 4201.06B | 4033.7B | 3530B | |
| P/E ratio | 37.28 | -132.95 | 103.88 | 973.45 | 106.44 | |
| Price to sales ratio | 5.09 | 21.11 | 25.47 | 23.18 | 20.78 | |
| POCF ratio | 33.65 | 272.92 | 689.53 | 415.05 | 193.45 | |
| PFCF ratio | 39.27 | 401.65 | 2.01K | 548.02 | 238.75 | |
| P/B Ratio | 3.68 | 17.78 | 19.58 | 18.66 | 16.48 | |
| PTB ratio | 3.68 | 17.78 | 19.58 | 18.66 | 16.48 | |
| EV to sales | 6.35 | 22.36 | 26.87 | 24.45 | 20.78 | |
| Enterprise value over EBITDA | 74.68 | 243.7 | 235.62 | 296.19 | 289.59 | |
| EV to operating cash flow | 41.92 | 289.08 | 727.39 | 437.74 | 193.45 | |
| EV to free cash flow | 48.92 | 425.43 | 2.12K | 577.98 | 238.75 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0.03 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.49 | 0.61 | 0.75 | 0.74 | 0 | |
| Debt to assets | 0.65 | 0.7 | 0.7 | 0.69 | 0.68 | |
| Net debt to EBITDA | 14.73 | 13.62 | 12.26 | 15.35 | 0 | |
| Current ratio | 1.43 | 1.3 | 1.46 | 1.52 | 1.22 | |
| Interest coverage | 4.57 | 4.43 | 5.64 | 3.39 | 20.39 | |
| Income quality | 4.43 | -1.95 | 0.6 | 9.38 | 2.2 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.16 | 0.14 | 0.14 | 0.34 | |
| Research and developement to revenue | 0.04 | 0.03 | 0.04 | 0.04 | 0 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0 | |
| Capex to operating cash flow | -0.14 | -0.32 | -0.66 | -0.24 | -0.19 | |
| Capex to revenue | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | |
| Capex to depreciation | -0.81 | -1.04 | -0.81 | -0.56 | -0.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.32K | 1.66K | 1.99K | 639.63 | 1.9K | |
| ROIC | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 | |
| Return on tangible assets | 0.01 | -0.01 | 0.02 | 0 | 0.01 | |
| Graham Net | -10.74K | -3.11K | -3.06K | -2.92K | -4.02K | |
| Working capital | 105.57B | 83.77B | 117.4B | 124.64B | 74.31B | |
| Tangible asset value | 187.89B | 167.07B | 170.23B | 171.8B | 0 | |
| Net current asset value | -32B | -78.06B | -74.59B | -68.51B | -7.71B | |
| Invested capital | 1.04 | 1.22 | 1.24 | 1.19 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 54.81B | 55.13B | 56.49B | 58.61B | 0 | |
| Average inventory | 110.73B | 107.01B | 109.29B | 111.48B | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 48.44 | 44.73 | 53.14 | 52.84 | 0 | |
| Days of inventory on hand | 104.45 | 88.8 | 104.7 | 100.51 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.86 | 2.01 | 1.69 | 1.7 | 0 | |
| Inventory turnover | 0.86 | 1.01 | 0.86 | 0.9 | 0 | |
| ROE | 0.02 | -0.03 | 0.05 | 0 | 0.04 | |
| Capex per share | -132.77 | -39.93 | -36.09 | -21.25 | -32.91 |
001065.KS Frequently Asked Questions
What is JW Pharmaceutical Corporation stock symbol ?
JW Pharmaceutical Corporation is a KR stock and trading under the symbol 001065.KS
What is JW Pharmaceutical Corporation stock quote today ?
JW Pharmaceutical Corporation stock price is $32450 today.
Is JW Pharmaceutical Corporation stock public?
Yes, JW Pharmaceutical Corporation is a publicly traded company.
Company Profile
- Volume Average 341
- Market Capitalization 797.67B
- Employee 1.13K
- CEO Mr. Young-Sub Shin
- Headquarters Seoul,KR
- IPO Date 2005-09-29
-
Website
https://www.jw-pharma.co.kr 
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
